AU719038B2 - Methods for diagnosing and treating Alzheimer's disease - Google Patents

Methods for diagnosing and treating Alzheimer's disease Download PDF

Info

Publication number
AU719038B2
AU719038B2 AU24245/97A AU2424597A AU719038B2 AU 719038 B2 AU719038 B2 AU 719038B2 AU 24245/97 A AU24245/97 A AU 24245/97A AU 2424597 A AU2424597 A AU 2424597A AU 719038 B2 AU719038 B2 AU 719038B2
Authority
AU
Australia
Prior art keywords
amyloid
growth factor
nerve growth
peptide
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU24245/97A
Other languages
English (en)
Other versions
AU2424597A (en
Inventor
Barbara A Gilchrest
Mina Yaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of AU2424597A publication Critical patent/AU2424597A/en
Application granted granted Critical
Publication of AU719038B2 publication Critical patent/AU719038B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
AU24245/97A 1996-03-29 1997-03-28 Methods for diagnosing and treating Alzheimer's disease Ceased AU719038B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62576596A 1996-03-29 1996-03-29
US08/625765 1996-03-29
PCT/US1997/004966 WO1997037228A1 (en) 1996-03-29 1997-03-28 Methods for diagnosing and treating alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2424597A AU2424597A (en) 1997-10-22
AU719038B2 true AU719038B2 (en) 2000-05-04

Family

ID=24507498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24245/97A Ceased AU719038B2 (en) 1996-03-29 1997-03-28 Methods for diagnosing and treating Alzheimer's disease

Country Status (8)

Country Link
US (3) US6242416B1 (OSRAM)
EP (1) EP0890105B1 (OSRAM)
JP (1) JP2000507828A (OSRAM)
AT (1) ATE346303T1 (OSRAM)
AU (1) AU719038B2 (OSRAM)
CA (1) CA2250075C (OSRAM)
DE (1) DE69736976T2 (OSRAM)
WO (1) WO1997037228A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755426B2 (en) * 1998-02-04 2002-12-12 Trustees Of Boston University Methods of inducing hair growth and coloration

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867179B1 (en) 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
IL147970A0 (en) * 1999-08-09 2002-09-12 Tripep Ab Pharmaceutical compositions containing tripeptides
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
KR20020007432A (ko) * 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
WO2003024995A1 (en) * 2001-09-19 2003-03-27 Tripep Ab Molecules that block viral infectivity and methods of use thereof
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
HK1079984A1 (zh) * 2003-02-21 2006-04-21 Tripep Ab 抑制hiv复制的甘氨酰胺衍生物
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
WO2004099237A1 (de) * 2003-05-08 2004-11-18 Pentapharm Ag Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
EP1718324A4 (en) * 2003-06-11 2009-07-15 Socratech L L C A SOLUBLE PROTEIN RELATED TO THE LOW DENSITY LIPOPROTEIN RECEPTOR BINDS DIRECTLY TO THE ALZHEIMER BETA AMYLOID PEPTIDE
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
WO2006116400A2 (en) * 2005-04-27 2006-11-02 Massachusetts Institute Of Technology Promoter engineering and genetic control
CA2667260A1 (en) * 2006-10-23 2008-05-02 National University Corporation Nagoya University Intracerebral oxidation inhibitor and use thereof
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
US9458427B2 (en) * 2009-08-07 2016-10-04 Case Western Reserve University IFNγR2 compositions and methods of inhibiting neuronal cell death
EP2498817A2 (en) * 2009-11-12 2012-09-19 F. Hoffmann-La Roche AG A method of promoting dendritic spine density
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP5863663B2 (ja) 2009-11-12 2016-02-16 ファーマトロフィックス， インコーポレイテッド ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
US9216217B2 (en) * 2010-03-03 2015-12-22 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
ES2628596T3 (es) 2010-11-29 2017-08-03 Akershus Universitetssykehus Procedimientos y composiciones para monitorizar la actividad fagocítica
EP2764120B1 (en) * 2011-10-05 2020-06-10 Blanchette Rockefeller Neurosciences, Institute Stimulus-elicited genomic profile markers of a neurodegenerative condition
US9534016B2 (en) * 2011-11-28 2017-01-03 Buck Institute For Research On Aging Netrin loop peptide mimetics and uses thereof
GB2516045A (en) * 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
ES2699410T3 (es) 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR
WO2018161211A1 (en) * 2017-03-06 2018-09-13 Nippon Zoki Pharmaceutical Co., Ltd. INHIBITING OR ALLEVIATING AGENT FOR Aβ-INDUCED DAMAGE
JP6359160B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN119661638B (zh) * 2024-11-22 2025-07-18 象山县第一人民医院医疗健康集团(宁波市第四医院、宁波市第四医院医院管理研究所) 一种修复神经损伤的多肽、制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4005195A (en) * 1994-10-24 1996-05-15 Regents Of The University Of California, The Method for increasing the resistance of neural cells to beta -amyloid peptide toxicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4918405A (en) * 1988-10-26 1990-04-17 Hewlett-Packard Company Signal generator utilizing a combined phase locked and frequency locked loop
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4005195A (en) * 1994-10-24 1996-05-15 Regents Of The University Of California, The Method for increasing the resistance of neural cells to beta -amyloid peptide toxicity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755426B2 (en) * 1998-02-04 2002-12-12 Trustees Of Boston University Methods of inducing hair growth and coloration

Also Published As

Publication number Publication date
ATE346303T1 (de) 2006-12-15
US20040254110A1 (en) 2004-12-16
EP0890105B1 (en) 2006-11-22
US6242416B1 (en) 2001-06-05
CA2250075C (en) 2008-06-10
JP2000507828A (ja) 2000-06-27
US6696303B2 (en) 2004-02-24
US20020051988A1 (en) 2002-05-02
AU2424597A (en) 1997-10-22
CA2250075A1 (en) 1997-10-09
EP0890105A1 (en) 1999-01-13
DE69736976D1 (de) 2007-01-04
DE69736976T2 (de) 2007-10-18
WO1997037228A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
AU719038B2 (en) Methods for diagnosing and treating Alzheimer's disease
Biere et al. Co-expression of β-amyloid precursor protein (βAPP) and apolipoprotein E in cell culture: analysis of βAPP processing
CN113476589A (zh) 肽在制造用于治疗神经退行性疾病的组合物中的用途
WO1998022499A9 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998022499A2 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1994009808A1 (en) Substances having the growth-promoting effect of amyloid precursor protein
AU681434B2 (en) Methods and compositions for binding TAU and MAP2c proteins
AU718498B2 (en) Methods of reducing apolipoprotein E4-induced inhibition of neuron remodeling
EP0593516B1 (en) Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
AU4099100A (en) Copper agonist that binds on the copper binding site of APP and/or exerts an inhibiting effect on the release of amyloid A beta peptide
US5811243A (en) Methods and compositions for binding tau and MAP2c proteins
US9402875B2 (en) Amidated dopamine neuron stimulating peptide restoration of mitochondrial activity
AU2002363524B2 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
US20010012506A1 (en) Endothelial-derived toxic factor
US20020009439A1 (en) Compounds effecting neuron remodeling and assays for same
AU2002255531B2 (en) Compounds effecting neuron remodeling and assays for same
AU2009227824A1 (en) Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
US20050159354A1 (en) Reagents and methods for treating epilepsy, traumatic injury and other pathologies of the brain
AU2002255531A1 (en) Compounds effecting neuron remodeling and assays for same
CA2221391A1 (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof
JPWO2000066145A1 (ja) 神経細胞株の細胞死を誘導する方法、神経細胞の細胞死を阻害または促進する化合物をスクリーニングする方法、ならびに神経細胞の細胞死の阻害剤および促進剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)